Diadema Partners LP Takes Position in argenx SE (NASDAQ:ARGX)

Diadema Partners LP acquired a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 679 shares of the company's stock, valued at approximately $422,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Stifel Financial Corp boosted its position in argenx by 6.8% during the 4th quarter. Stifel Financial Corp now owns 9,433 shares of the company's stock valued at $5,801,000 after buying an additional 601 shares during the period. Mirabella Financial Services LLP bought a new position in shares of argenx during the fourth quarter valued at about $2,539,000. MML Investors Services LLC boosted its holdings in shares of argenx by 1.7% during the fourth quarter. MML Investors Services LLC now owns 8,844 shares of the company's stock worth $5,439,000 after purchasing an additional 145 shares during the period. Capital World Investors grew its stake in shares of argenx by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock worth $1,099,002,000 after purchasing an additional 86,687 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in argenx by 21.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock valued at $15,332,000 after purchasing an additional 4,445 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX traded up $14.25 during trading on Friday, reaching $614.76. 215,836 shares of the company's stock traded hands, compared to its average volume of 308,025. The stock has a market capitalization of $37.54 billion, a P/E ratio of -698.59 and a beta of 0.60. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The company has a 50 day moving average of $598.28 and a 200-day moving average of $607.83.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. Equities research analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on ARGX shares. Truist Financial reaffirmed a "buy" rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Wedbush reaffirmed an "outperform" rating and issued a $715.00 price target on shares of argenx in a research note on Friday, April 11th. Wells Fargo & Company boosted their target price on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Finally, Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.